Health Care·Biotechnology·$7.7B
ImmunityBio Inc (IBRX) is a biotechnology company focused on developing innovative immunotherapy treatments for cancer and infectious diseases. As a player in the health care sector, its advancements could significantly impact patient outcomes and the overall treatment landscape.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
While specific revenue figures are not available, any indication of growth in this area would signal strong demand for its therapies.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
2Q
EPS Beat Rate
50%
Avg EPS Surprise
+8.61%
Avg Stock Reaction
+0.87%
In the last quarter (Q4-2025), ImmunityBio reported an EPS of -$0.06, outperforming expectations by 25%. The stock reacted positively, gaining nearly 13% the following day.
Management Promises & Guidance
Overall expectations for ImmunityBio's upcoming earnings are uncertain due to a lack of analyst estimates and guidance. Investors will be keenly watching for any signs of progress in clinical trials.
Bull Case
If the company reports better-than-expected clinical trial results and shows signs of revenue growth, it could lead to a significant stock price increase.
Bear Case
Conversely, if the company fails to provide positive updates on its trials or shows continued losses, it may lead to a decline in investor confidence and stock price.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AWhile specific revenue figures are not available, any indication of growth in this area would signal strong demand for its therapies.
Clinical Trial Updates
N/AUpdates on ongoing clinical trials can provide insight into the company's future prospects and potential market success.
The print will turn on these two things.
Q1
What specific updates can management provide on ongoing clinical trials?
Investors are looking for concrete data that could indicate the potential success of ImmunityBio's therapies and their market readiness.
Q2
Will there be any guidance on revenue expectations for the upcoming quarters?
Clear revenue guidance can help set investor expectations and provide insight into the company's financial trajectory.
Why consensus could be wrong
The Street may be underestimating the potential impact of ImmunityBio's clinical trial results, which could exceed current expectations and drive significant revenue growth.
Supporting Evidence
The company has a strong history of beating EPS estimates, with a 63% success rate over the last 8 quarters.
Recent positive reactions to earnings surprises suggest that investor sentiment may be more favorable than anticipated.
The lack of analyst estimates could lead to a more pronounced reaction to any positive news.
Key Risk
If the clinical trial results show significant promise, it could shift the narrative and lead to a reevaluation of the company's potential.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to translate its research into successful therapies and revenue generation.
Bull Confirmed If
Positive updates from clinical trials leading to a projected revenue growth of at least 15% year-over-year.
Bear Confirmed If
Failure to meet clinical trial milestones or continued losses exceeding $0.10 EPS.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Cross-company pattern from 30 similar setups.
Prior-quarter beat setup in Health Care
n=30Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.9%, with a raw directional average of +2.3% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If ImmunityBio beats expectations, history suggests the stock could rise by an average of 7.17%, confirming a positive outlook for its therapies.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.
Miss
In the event of a miss, the stock could decline by an average of 4.38%, indicating disappointment in the company's progress.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ADOBE INC
Mar 23, 2021